Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma

Unresectable malignant pleural mesothelioma (MPM) is an aggressive disease with a 5-year survival rate of approximately 10%. Recent data suggest that MPM is an immunologically active tumor, in which checkpoint inhibition through the blockade of the anti-cytotoxic T lymphocyte antigen-4 (-CTLA-4) or...

Full description

Bibliographic Details
Main Authors: Giulio Metro, Diego Signorelli, Elio G. Pizzutilo, Laura Giannetta, Giulio Cerea, Miriam Garaffa, Alex Friedlaender, Alfredo Addeo, Martina Mandarano, Guido Bellezza, Fausto Roila
Format: Article
Language:English
Published: Taylor & Francis Group 2021-09-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immune checkpoint inhibitors
immunotherapy
malignant pleural mesothelioma
pd-(l)1
Online Access:http://dx.doi.org/10.1080/21645515.2021.1917933

Similar Items

Similar Items